These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22006123)

  • 1. A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma.
    Cheson BD; Bartlett NL; Vose JM; Lopez-Hernandez A; Seiz AL; Keating AT; Shamsili S; Papadopoulos KP
    Cancer; 2012 Jun; 118(12):3128-34. PubMed ID: 22006123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma.
    Kaneko N; Mitsuoka K; Amino N; Yamanaka K; Kita A; Mori M; Miyoshi S; Kuromitsu S
    Clin Cancer Res; 2014 Apr; 20(7):1814-22. PubMed ID: 24486595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma.
    Papadopoulos KP; Lopez-Jimenez J; Smith SE; Steinberg J; Keating A; Sasse C; Jie F; Thyss A
    Leuk Lymphoma; 2016 Aug; 57(8):1848-55. PubMed ID: 26857688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma.
    Lewis KD; Samlowski W; Ward J; Catlett J; Cranmer L; Kirkwood J; Lawson D; Whitman E; Gonzalez R
    Invest New Drugs; 2011 Feb; 29(1):161-6. PubMed ID: 19830389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors.
    Satoh T; Okamoto I; Miyazaki M; Morinaga R; Tsuya A; Hasegawa Y; Terashima M; Ueda S; Fukuoka M; Ariyoshi Y; Saito T; Masuda N; Watanabe H; Taguchi T; Kakihara T; Aoyama Y; Hashimoto Y; Nakagawa K
    Clin Cancer Res; 2009 Jun; 15(11):3872-80. PubMed ID: 19470738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.
    Tolcher AW; Mita A; Lewis LD; Garrett CR; Till E; Daud AI; Patnaik A; Papadopoulos K; Takimoto C; Bartels P; Keating A; Antonia S
    J Clin Oncol; 2008 Nov; 26(32):5198-203. PubMed ID: 18824702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of YM155, a survivin suppressant with a STAT3 inhibitor: a new strategy to treat diffuse large B-cell lymphoma.
    Kaneko N; Kita A; Yamanaka K; Mori M
    Leuk Res; 2013 Sep; 37(9):1156-61. PubMed ID: 23746965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer.
    Tolcher AW; Quinn DI; Ferrari A; Ahmann F; Giaccone G; Drake T; Keating A; de Bono JS
    Ann Oncol; 2012 Apr; 23(4):968-73. PubMed ID: 21859898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.
    Kelly RJ; Thomas A; Rajan A; Chun G; Lopez-Chavez A; Szabo E; Spencer S; Carter CA; Guha U; Khozin S; Poondru S; Van Sant C; Keating A; Steinberg SM; Figg W; Giaccone G
    Ann Oncol; 2013 Oct; 24(10):2601-2606. PubMed ID: 23857959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.
    Nakahara T; Kita A; Yamanaka K; Mori M; Amino N; Takeuchi M; Tominaga F; Hatakeyama S; Kinoyama I; Matsuhisa A; Kudoh M; Sasamata M
    Cancer Res; 2007 Sep; 67(17):8014-21. PubMed ID: 17804712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma.
    Yu Y; Zhao X; Zhang Y; Kang Y; Wang J; Liu Y
    Oncol Rep; 2015 Jul; 34(1):407-14. PubMed ID: 25955434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effect of YM155, a novel small-molecule survivin suppressant, via mitochondrial apoptosis in human MFH/UPS.
    Minoda M; Kawamoto T; Ueha T; Kamata E; Morishita M; Harada R; Toda M; Onishi Y; Hara H; Kurosaka M; Akisue T
    Int J Oncol; 2015 Sep; 47(3):891-9. PubMed ID: 26166250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
    Yamanaka K; Nakahara T; Yamauchi T; Kita A; Takeuchi M; Kiyonaga F; Kaneko N; Sasamata M
    Clin Cancer Res; 2011 Aug; 17(16):5423-31. PubMed ID: 21737502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer.
    Shimizu T; Nishio K; Sakai K; Okamoto I; Okamoto K; Takeda M; Morishita M; Nakagawa K
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):211-219. PubMed ID: 32638093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma.
    Kita A; Nakahara T; Yamanaka K; Nakano K; Nakata M; Mori M; Kaneko N; Koutoku H; Izumisawa N; Sasamata M
    Leuk Res; 2011 Jun; 35(6):787-92. PubMed ID: 21237508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer.
    Giaccone G; Zatloukal P; Roubec J; Floor K; Musil J; Kuta M; van Klaveren RJ; Chaudhary S; Gunther A; Shamsili S
    J Clin Oncol; 2009 Sep; 27(27):4481-6. PubMed ID: 19687333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of Survivin Pathways by YM155 Inhibits Cell Death and Invasion in Oral Squamous Cell Carcinoma Cells.
    Zhang W; Liu Y; Li YF; Yue Y; Yang X; Peng L
    Cell Physiol Biochem; 2016; 38(6):2426-37. PubMed ID: 27287458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silencing of survivin using YM155 induces apoptosis and chemosensitization in neuroblastomas cells.
    Liang H; Zhang L; Xu R; Ju XL
    Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2909-15. PubMed ID: 24254560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model.
    Nakahara T; Yamanaka K; Hatakeyama S; Kita A; Takeuchi M; Kinoyama I; Matsuhisa A; Nakano K; Shishido T; Koutoku H; Sasamata M
    Anticancer Drugs; 2011 Jun; 22(5):454-62. PubMed ID: 21389848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic antitumor activities of sepantronium bromide (YM155), a survivin suppressant, in combination with microtubule-targeting agents in triple-negative breast cancer cells.
    Kaneko N; Yamanaka K; Kita A; Tabata K; Akabane T; Mori M
    Biol Pharm Bull; 2013; 36(12):1921-7. PubMed ID: 24432379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.